Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone

This study has been completed.
Sponsor:
Information provided by:
Gynuity Health Projects
ClinicalTrials.gov Identifier:
NCT01387256
First received: May 2, 2011
Last updated: July 18, 2011
Last verified: July 2011
  Purpose

This double blinded, placebo-controlled randomized trial will compare the safety, efficacy and acceptability of two medical abortion regimens up to 63 days since last Menstrual Period (LMP) in Tunisia and Vietnam. The first regimen will include a 200 mg oral dose of mifepristone followed by 800 mcg buccal misoprostol. The second regimen will include two 800 mcg doses of buccal misoprostol three hours apart. All drugs are administered AT home by the participant.


Condition Intervention Phase
Complete Abortion
Drug: medical abortion
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone-3 Hour Intervals

Resource links provided by NLM:


Further study details as provided by Gynuity Health Projects:

Primary Outcome Measures:
  • Number of women with a complete abortion using study drug alone without recourse to surgical intervention [ Time Frame: one week from initial treatment ] [ Designated as safety issue: Yes ]
    Number of participants with a complete abortion after treatment without recourse to surgical intervention as a measure of efficacy of the study regimens


Secondary Outcome Measures:
  • Number of women who indicate that the side effects of buccal misoprostol, administered either alone or in combination with mifepristone, is acceptable in Tunisia and Vietnam [ Time Frame: one week from initial treatment ] [ Designated as safety issue: Yes ]
    Proportion of women who report the side effects after their treatment to be acceptable as a measure of acceptability with the buccal misoprostol route (with and without mifepristone)

  • Evaluate whether women administering buccal misoprostol have a complete abortion with study drug and experience any adverse events, at a rate that is similar to other routes of misoprostol administration [ Time Frame: one week from initial treatment ] [ Designated as safety issue: Yes ]
    To assess the rate of complete uterine evacuation with study drugs alone and rate of any adverse events among participants after use of buccal misoprostol (alone or with mifepristone)as a measure of its utility in early medical abortion compared to other regimens

  • Measuring the proportion of women who report their medical abortion procedure to be acceptable in Tunisia and Vietnam [ Time Frame: one week from initial treatment ] [ Designated as safety issue: No ]
    Proportion of participants reporting that they found the medical abortion regimen assigned to them to be acceptable

  • Determining whether women can take both the mifepristone and misoprostol at home on their own by assessing protocol compliance [ Time Frame: one week from initial treatment ] [ Designated as safety issue: No ]
    Proportion of women who report taking mifepristone and misoprostol at home on their own as instructed as a measure of compliance and feasibility of a protocol with at home administration of study drugs


Enrollment: 441
Study Start Date: May 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
mifepristone+misoprostol
200 mg mifepristone + 800 mcg buccal misoprostol
Drug: medical abortion
pregnancy termination with drugs
Experimental: buccal misoprostol
2 doses of 800 mcg buccal misoprostol
Drug: medical abortion
pregnancy termination with drugs

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Gestational age < 63 days since LMP, confirmed by ultrasound or clinical assessment.
  • General good health including absence of conditions which contraindicate the use of mifepristone and misoprostol for pregnancy termination.
  • Agrees to return for follow-up visit and willing to provide an address and/or telephone number for purposes of follow-up.
  • Able to consent to study participation.

Exclusion Criteria:

  • Gestational age > 63 days LMP
  • Confirmed or suspected ectopic or molar pregnancy
  • Contraindications to medical abortion including intra-uterine device (IUD) in place (must be removed before procedure), chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, misoprostol or prostaglandin, hemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyries.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01387256

Locations
Tunisia
La Rabta Maternity Hospital
Tunis, Tunisia
Vietnam
Hung Vuong Hospital
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
Gynuity Health Projects
  More Information

No publications provided

Responsible Party: Dr Beverly Winikoff, Gynuity Health Projects
ClinicalTrials.gov Identifier: NCT01387256     History of Changes
Other Study ID Numbers: 1.2.1
Study First Received: May 2, 2011
Last Updated: July 18, 2011
Health Authority: Vietnam: Ministry of Health
Tunisia: Ministry of Public Health

Keywords provided by Gynuity Health Projects:
abortion
mifepristone
misoprostol
with gestations > 63 days LMP

Additional relevant MeSH terms:
Mifepristone
Misoprostol
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents, Steroidal
Anti-Ulcer Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Contraceptives, Postcoital
Contraceptives, Postcoital, Synthetic
Gastrointestinal Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents
Oxytocics
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014